Search

Now showing items 1-8 of 8

Chromosome aberrations after high-dose 131I and 99mTc-MIBI administration using a micronucleus assay

Asli, IN; Mosaffa, N; Mogharrabi, M; Hooman, A; Tabei, F; Javadi, H; Shafei, B; Seyedabadi, M; Assadi, M (2010)

Objective: We evaluated the potential detrimental cytogenetic effects of 99mTc-methoxyisobutyl isonitrile (MIBI) and 131I on patients who were exposed to the radiopharmaceutics for cardiac imaging or thyroid cancer therapy, ...

Relation between clinical and laboratory parameters with radiation dose rates from patients receiving iodine-131 therapy for thyroid carcinoma

Asli, IN; Baharfard, N; Shafiei, B; Tabei, F; Javadi, H; Seyedabadi, M; Nabipour, I; Assadi, M (2009)

Three days following administration of radioactive iodine in 38 patients, exposure rates such as dose rate close to the dress (D0), dose rate of dress at 1 m (D1), dose rate close to the bedsheet (B0), dose rate of bedsheet ...

Scintigraphic parameters with emphasis on perfusion appraisal in rest 99mTc-sestamibi SPECT in the recovery of myocardial function after thrombolytic therapy in patients with ST elevation myocardial infarction (STEMI)

Javadi, H; Porpiranfar, MA; Semnani, S; Jallalat, S; Yavari, P; Mogharrabi, M; Hooman, A; Amini, A; Barekat, M; Iranpour, D; Seyedabadi, M; Assadi, M; Asli, IN (2011)

Introduction: This study was performed to determine the clinical application of rest 99mTc-sestamibi in the assessment of viability and functional improvement of the left ventricle (LV) myocardium in the post-thrombolytic ...

Pathological evaluation of differentiated thyroid cancer in patients with positive serum thyroglobulin and negative iodine scan

Assadi, M; Babaei, AA; Shafiei, B; Javadi, H; Assadi, M; Nabipour, I; Asli, IN (2014)

OBJECTIVE: There is no investigation that emphasizes the pathology of DTC (differentiated thyroid cancer) patients with positive Tg and negative iodine scan. The present study was performed to assess the pathology of these ...

Phase 2 study of a high dose of 186RE-HEDP for bone pain palliation in patients with widespread skeletal metastases

Pirayesh, E; Amoui, M; Mirzaee, HR; Tabei, F; Rakhsha, A; Kalantari, BA; Shafiei, B; Assadi, M; Asli, IN (2013)

186Re-1-hydroxyethylidene-1,1-diphosphonate (HEDP) is an attractive radiopharmaceutical for the treatment of bone pain arising from skeletal metastatic lesions. Currently, 186Re-HEDP is most commonly used in European ...

A study of the time of hospital discharge of differentiated thyroid cancer patients after receiving iodine-131 for thyroid remnant ablation treatment

Azizmohammadi, Z; Tabei, F; Shafiei, B; Babaei, AA; Jukandan, SMQ; Naghshine, R; Javadi, H; Nabipour, I; Assadi, M; Asli, IN (2013)

The aim of this study was to measure the radiation exposure rate from differentiated thyroid carcinoma (DTC) patients who had received iodine-131 (131I) treatment, and to evaluate hospital discharge planning in relation ...

Assessment of radioiodine clearance in patients with differentiated thyroid cancer

Tabei, F; Asli, IN; Azizmohammadi, Z; Javadi, H; Assadi, M (2012)

Radioiodine (131I iodide) has long been a safe, effective and widely used treatment in the management of differentiated thyroid cancer (DTC). Concerns regarding stochastic radiogenic risks have led to regulatory criteria ...

Comparison of three with six regions of interest analyses in patients with idiopathic constipation undertaking colon transit scintigraphy using 67Ga-citrate

Asli, IN; Ehsani, MJ; Javadi, H; Semnani, S; Tabib, SM; Assadi, M (2013)

OBJECTIVE AND INTRODUCTION: Preparation of data from 6 geometric regions of interest in the colon is time consuming, and can become impractical in the environment of busy Nuclear Medicine Departments. Therefore, we have ...